Advertisement
Organisation › Details
Biovitrum (Group)
Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. *
Start | 2001-01-01 splitoff | |
End | renamed | |
Group | Swedish Orphan Biovitrum (Sobi) (Group) | |
Today | Swedish Orphan Biovitrum (Sobi) (Group) | |
Predecessor | Pharmacia | |
Successor | Swedish Orphan Biovitrum (Sobi) (Group) | |
Industry | BIOTECH | |
Region | Stockholm | |
Country | Sweden | |
Street | Berzelius väg 8 | |
City | 112 76 Stockholm | |
Tel | +46-8-697-2000 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2007-12-31) |
Currency | SEK | |
Annual sales | 1,256,400,000 (revenues, total, consolidated (2007) 2007-12-31) | |
Profit | 79,000,000 (2007-12-31) | |
Cash | 760,400,000 (2007-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Swedish Orphan Biovitrum (Sobi) (Group)
- [1] ADC Therapeutics S.A.. (12/21/22). "Press Release: ADC Therapeutics and Sobi Announce European Commission Approval of Zynlonta (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma". Lausanne....
- [2] ADC Therapeutics S.A.. (7/8/22). "Press Release: ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Europe and Select International Territories". Lausanne....
- [3] Swedish Orphan Biovitrum AB. (12/21/20). "Press Release: Sobi Appoints New Head of North America Ahead of Launch Phase"....
- [4] AstraZeneca plc. (8/22/19). "Press Release: AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi"....
- [5] Swedish Orphan Biovitrum AB. (10/24/17). "Press Release: Sobi Establishes New Leadership Structure and Appoints Torbjörn Hallberg as General Counsel"....
- [6] Swedish Orphan Biovitrum AB. (10/6/17). "Press Release: Norbert Oppitz Joins Sobi as New Senior Vice President, Specialty Care"....
- [7] PCI Biotech Holding ASA. (8/23/17). "Press Release: PCI Biotech Appoints Dr Hans Olivecrona as Chief Medical Officer". Oslo....
- [8] Swedish Orphan Biovitrum AB. (5/4/17). "Press Release: Guido Oelkers Appointed President and CEO at Sobi"....
- [9] Swedish Orphan Biovitrum AB. (5/3/17). "Press Release: Sobi Opens Office in Greece"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top